French to slash reimbursement of benzodiazepine hypnotics
This article was originally published in SRA
Executive Summary
French sales of major hypnotics containing benzodiazepine and BDZ-related hypnotic drugs, including temazepam and zolpidem, are likely to be hit after the French health technology body, the HAS, downgraded their medical benefit rating and recommended a cut in their reimbursement from 65% to 15% because of concerns over their safety and efficacy profile1,2.